Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation

Bibliography

• World Health Organization. Fact sheets-epilepsy. 2012. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/
   Google Scholar
• Kuo CC, Lin BJ, Chang HR, Hsieh CP. Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. Mol Pharmacol 2004;65:370-80
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18-61
   PubMed Web of Science ®Google Scholar
• Gibbs JWIII, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):10-16
   PubMed Web of Science ®Google Scholar
• Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit 2007;13:1-7
   Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304. Neurology 2012;79(6):589-96
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patient with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia 2013;54:117-25
   PubMed Web of Science ®Google Scholar
• Beneyto M, Meador-Woodruff JH. Expression of transcripts encoding AMPA receptor subunits and associated postsynaptic proteins in the macaque brain. J Comp Neurol 2004;468:530-54
   PubMed Web of Science ®Google Scholar
• Chater TE, Goda Y. The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity. Front Cell Neurosci 2014;8:401
   PubMed Web of Science ®Google Scholar
• Swanson GT, Kamboj SK, Cull-Candy SG. Single-channel properties of recombinant AMPA receptors dependon RNA editing, splice variation and subunit composition. J Neurosci 1997;17:58-69
   PubMed Web of Science ®Google Scholar
• McBain CJ, Boden P, Hill RG. The kainate/quisqualate receptor antagonist, CNQX, blocks the fast component of spontaneous epileptiform activity in organotypic cultures of rat hippocampus. Neurosci Lett 1988;93:341-5
   PubMed Web of Science ®Google Scholar
• Neuman RS, Ben-Ari Y, Cherubini E. Antagonism of spontaneous and evoked bursts by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the CA3 region of the in vitro hippocampus. Brain Res 1988;474:201-3
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Excitotoxicity and selective neuronal loss in epilepsy. Brain Pathol 1993;3:405-12
   PubMed Web of Science ®Google Scholar
• Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch Eur J Physiol 2010;460:525-42
   PubMed Web of Science ®Google Scholar
• Citraro R, Aiello R, Franco V, et al. Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. Expert Opin Ther Targets 2014;18:319-34
   PubMed Web of Science ®Google Scholar
• Croucher MJ, Collins JF, Meldrum BS. Anticonvulsant action of excitatory amino acid antagonists. Science 1982;216:899-901
   PubMed Web of Science ®Google Scholar
• Löscher W, Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP37849 and CGP 39551, in the kindling model of epilepsy: comparison with MK-801 and carbamazepine. J Pharmacol Exp Ther 1991;256:432-40
   PubMed Web of Science ®Google Scholar
• Sveinbjornsdottir S, Sander JW, Upton D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993;16:165-74
   PubMed Web of Science ®Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand 2013;127(Suppl 197):19-24
   PubMed Web of Science ®Google Scholar
• Zwart R, Sher E, Ping X, et al. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. J Pharmacol Exp Ther 2014;351:124-33
   PubMed Web of Science ®Google Scholar
• Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov 2014;9:449-58
   PubMed Web of Science ®Google Scholar
• Wu T, Nagaya Y and Hanada T. Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model. Seizure 2014;23:732-9
   PubMed Web of Science ®Google Scholar
• Danober L, Deransart C, Depaulis A, et al. Pathophysiological mechanisms of genetic absence epilepsy in the rat. Prog Neurobiol 1998;55:27-57
   PubMed Web of Science ®Google Scholar
• Citraro R, Russo E, Gratteri S, et al. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006;51:1058-67
   PubMed Web of Science ®Google Scholar
• Hanada T, Ido K and Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharma Res Persp 2014;2(5):10.1002/prp2.63
   Google Scholar
• Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: A pooled-response analysis of phase III studies. Epilepsia 2014;55:423-31
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia 2014;55:1058-68
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Hamer H, Trinka E, et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res 2014;108:986-8
   PubMed Web of Science ®Google Scholar
• Rugg-Gunn F. Adverse effects and safety profile of perampanel: A review of pooled data. Epilepsia 2014;55(Suppl 1):13-15
   PubMed Web of Science ®Google Scholar
• Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: Long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Cincotta M, et al. The adverse event profile of perampanel: Meta-analysis of randomized controlled trials. Eur J Neurol 2013;20:1204-11
   PubMed Web of Science ®Google Scholar
• Leppik IE, Wechsler RT, Williams B, et al. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res 2015;110:216-20
   PubMed Web of Science ®Google Scholar
• Hoppner AC, Fauser S, Kerling F. Clinical course of intoxication with the new anticonvulsant drug perampanel. Epileptic Disord 2013;15(3):362-4
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Cincotta M, Iudice A. AMPA receptor inhibitors for the treatment of epilepsy: The role of perampanel. Expert Rev. Neurother 2013;13:647-55
   Web of Science ®Google Scholar
• Shimabukuro K1, Gibbon F2, Kerstetter J2, Tinsley C2, Ashwal S2. DRESS associated with perampanel administration in a child with drug-resistant epilepsy. Neurology 2014;83:2188
   PubMedGoogle Scholar
• US Food and Drug Administration FDA. Clinical pharmacology review. Reference ID: 3205587 2012.http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM332052.pdf
   Google Scholar
• European Medicines Agency EMA, Fycompa SPC. Perampanel (Fycompa). Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf [Updated 13 November 2013]
   Google Scholar
• Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor. Epilepsia 2015;56:12-27
   PubMed Web of Science ®Google Scholar
• Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Poster # P2.231, presented at the 65th American Epilepsy Society, (AES) Annual Meeting; 2 - 6 December 2011; Baltimore, MD, USA; 2011
   Google Scholar
• Brown PC. Teritiary Pharmacology Review – Perampanel. Center for drug evaluation and research, Pharmacology Review. Available from: www.fda.gov 2011
   Google Scholar
• Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14
   PubMed Web of Science ®Google Scholar
• Novy J, Rothuizen LE, Buclin T, Rossetti AO. Perampanel: a significant liver enzyme inducer in some patients? Eur Neurol 2014;72:213-16
   PubMed Web of Science ®Google Scholar
• Gidal BE, Majid O, Ferry J, et al. The practical impact of altered dosing on perampanel plasma concentrations: Pharmacokinetic modeling from clinical studies. Epilepsy Behav 2014;35:6-12
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-17
   PubMed Web of Science ®Google Scholar
• Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand 2013;127(Suppl 197):3-8
   Google Scholar
• Mifsud J. The clinical relevance of pharmacokinetics and drug interactions with anti epileptic drugs. J Malta Coll Pharm Pract 2009;15:23-8
   Google Scholar
• Almeida L, Falcão A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005;45:1062-6
   PubMed Web of Science ®Google Scholar
• Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord 2014;16:395-408
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010;50:941-50
   PubMed Web of Science ®Google Scholar